Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic®) is safe in kidney transplant patients

Clinical Nephrology

Volumn 66, Issue 2, 2006, Pages 112-119

  Salvadori, M ^a   Holzer, H ^b   Civati, G ^c   Sollinger, H ^d   Lien, B ^e   Tomlanovich, S ^f   Bertoni, E ^a   Seifu, Y ^g   Marrast, A C ^g   de Mattos, Angelo ^h   Bennett, William ^h   Kumar, Mysore ⁱ   Margreiter, Raymond ^j   Muehlbacher, Ferdinand ^k   Kalmar Nagy, Karoly ^l   Wilkie, Martin ^m   Brayman, Kenneth ⁿ   Barker, Clyde ⁿ   Perner, Ferenc ^o   Gentil, Miguel ^p   Gonzalez Molina, Miguel ^q   Russell, David ^r   Sperschneider, Heide ^s   Barama, A ^t   Yilmaz, Serder ^t   Szenohradszky, Pal ^u   Asztalos, L ^v   Abendroth, Dietmar ^w   del Castillo, Domingo ^x   Krämer, Bernhard ^y   Arns, Wolfgang ^z   Douzdijan, Viken ^aa   Bajjoka, Igor ^aa   Seifu, Yodit ^g   Marrast, Anne Claire ^g   more..

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF SAN FRANCISCO   (United States)

^g NOVARTIS PHARMA AG   (Switzerland)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^j Universitatsklinik fur Chirurgie Innsbruck   (Austria)

^k MEDICAL UNIVERSITY OF VIENNA   (Austria)

^l UNIVERSITY OF PÉCS   (Hungary)

^m NORTHERN GENERAL HOSPITAL   (United Kingdom)

ⁿ UNIVERSITY OF PENNSYLVANIA   (United States)

^o SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^p HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^q HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^r ST JOSEPH S HOSPITAL   (Canada)

^s FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^t FOOTHILLS HOSPITAL   (Canada)

^u UNIVERSITY OF SZEGED   (Hungary)

^v Orvostvdomanyi   (Hungary)

^w UNIVERSITY HOSPITAL ULM   (Germany)

^x HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^y UNIVERSITY OF REGENSBURG   (Germany)

^z UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^aa HENRY FORD HOSPITAL   (United States)

more..

Author keywords

Conversion; Mycophenolate mofetil; Mycophenolate sodium; Myfortic ; Renal transplantation

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; EVEROLIMUS; MYCOPHENOLIC ACID;

ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENTERIC COATED TABLET; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; INCIDENCE; INFECTION; KAPOSI SARCOMA; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LONG TERM CARE; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; NEUTROPENIA; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; SKIN CANCER; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 33747104149     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Budde K, Curtis J, Knoll G, Chan L, Neumayer HH, Seifu Y, Hall M on behalf of the ERL B302 Study Group. Enteric-coated mycophenolate sodium can be safety administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant. 2003; 4: 237-243.
2. Budde K, Glander P, Diekmann F, Waiser F, Fritsche L, Dragun D, Neumayer HH. Review of the immunosuppressant enteric-coated mycophenolate sodium. Exp Opin Pharmacother. 2004; 5: 1333-1345.
3. Budde K, Glander P, Hahn U et al. Pharmacokinetic and pharmacodynamic comparison of mycophenolic mofetil and enteric-coated mycophenolate sodium in maintenance transplant patients. Am J Transplant. 2002; 2: 399
4. Budde K, Knoll G, Curtis J et al. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic®). Clin Nephrol. 2006; (submitted).
5. Lorber MI, Mulgaonkar S, Butt KM, Elkhammas E, Mendez R, Rajagopalan PR, Kahan B, Sollinger H, Li Y, Cretin N, Tedesco H, B251 Study Group. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation. 2005; 80: 244-252.
6. Meier-Kriesche HU, Steffen BJ, Hochberg AM, Gordon RD, Liebman MN, Morris JA, Kaplan B. Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation. 2003; 75: 1341-1346.
7. Ojo A, Meier-Kriesche HU, Hanson JA, Leichtman AB, Cibrik D, Magee JC, Wolfe RA, Agodoa LY, Kaplan B. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation. 2000; 69: 2405-2409.
8. Salvadori M, Holzer H, de Mattos A, Sollinger H, Arns W, Oppenheimer F, Maca J, Hall M on behalf of the ERL B301 Study Groups. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant. 2003; 4: 231-236.
9. Sollinger HW for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation. 1995; 60: 225-232.
10. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized, clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation. 1996; 61: 1029-1037.
11. Vitko S, Margreiter R, Weimar W, Dantal J, Viljoen HG, Li Y, Jappe A, Cretin N, RAD B201 Study Group. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation. 2004; 78: 1532-1540.